Ligand Pharmaceuticals LGND Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number

Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number at other companies

MSCIMSCI

97K—

AmetekAME

1.6M-9.8%

Arthur J. GallagherAJG

3.1M—

L3Harris TechnologiesLHX

1.3M-32.2%

Mondelez InternationalMDLZ

12M-3.1%

General DynamicsGD

5.8M-11.6%

Other financials

Income statement

See full

Revenue$51.7M+14.1%

Operating income$17.4M+148%

Net income-$13.3M+68.6%

EPS (diluted)-$0.67+69.7%

Balance sheet

See full

Cash & equivalents$115.1M+140%

Total debt$5.1M+14.2%

Total equity$997.3M+25.4%

Total assets$1.5B+69.2%

Cash flow

See full

Operating cash flow$48.7M+291%

CapEx$228.0K+6.5%

Free cash flow$48.5M+289%

Valuation

See full

Market cap$5.6B+96.7%

Profitability

See full

Gross margin91.9%—

Operating margin34.5%+23.0pp

Net margin55.9%+35.7pp

FCF margin44.8%+16.8pp

Returns & leverage

See full

Return on equity17.1%+11.5pp

Debt / equity0×0.0×

Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's share based compensation arrangement by share based payment award options exercisable number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ligand Pharmaceuticals's share based compensation arrangement by share based payment award options exercisable number?: Ligand Pharmaceuticals (LGND) reported share based compensation arrangement by share based payment award options exercisable number of $1.1M in Q1 2026.
How has Ligand Pharmaceuticals's share based compensation arrangement by share based payment award options exercisable number changed year-over-year?: Ligand Pharmaceuticals's share based compensation arrangement by share based payment award options exercisable number decreased by 15.4% year-over-year, from $1.3M to $1.1M.